(Auto)antigen engagement by the B-cell receptor (BCR) and possibly the sites where this occurs influence the outcome of chronic lymphocytic leukemia (CLL). To test if selection for autoreactivity leads to increased aggressiveness and if this selection plays out equally in primary and secondary tissues, we used T-cell leukemia (TCL)1 cells reactive with the autoantigen phosphatidylcholine (PtC). After repeated transfers of splenic lymphocytes from a single mouse with oligoclonal PtC-reactive cells, outgrowth of cells expressing a single IGHV-D-J rearrangement and superior PtC-binding and disease virulence occurred. In secondary tissues, increased PtCbinding correlated with enhanced BCR signaling and cell proliferation, whereas reduced signaling and division of cells from the same clone was documented in cells residing in the bone marrow, blood, and peritoneum, even though cells from the last site had highest surface membrane IgM density. Gene-expression analyses revealed reciprocal changes of genes involved in BCR-, CD40-, and PI3K-signaling between splenic and peritoneal cells. Our results suggest autoantigen-stimulated BCR signaling in secondary tissues promotes selection, expansion, and disease progression by activating pro-oncogenic signaling pathways, and that-outside secondary lymphoid tissues-clonal evolution is retarded by diminished BCR-signaling. This transferrable, antigenic-specific murine B-cell clone (TCL1-192) provides a platform to study the types and sites of antigen-BCR interactions and genetic alterations that result and may have relevance to patients.
(Auto)antigen engagement by the B-cell receptor (BCR) and possibly the sites where this occurs influence the outcome of chronic lymphocytic leukemia (CLL). To test if selection for autoreactivity leads to increased aggressiveness and if this selection plays out equally in primary and secondary tissues, we used T-cell leukemia (TCL)1 cells reactive with the autoantigen phosphatidylcholine (PtC). After repeated transfers of splenic lymphocytes from a single mouse with oligoclonal PtC-reactive cells, outgrowth of cells expressing a single IGHV-D-J rearrangement and superior PtC-binding and disease virulence occurred. In secondary tissues, increased PtCbinding correlated with enhanced BCR signaling and cell proliferation, whereas reduced signaling and division of cells from the same clone was documented in cells residing in the bone marrow, blood, and peritoneum, even though cells from the last site had highest surface membrane IgM density. Gene-expression analyses revealed reciprocal changes of genes involved in BCR-, CD40-, and PI3K-signaling between splenic and peritoneal cells. Our results suggest autoantigen-stimulated BCR signaling in secondary tissues promotes selection, expansion, and disease progression by activating pro-oncogenic signaling pathways, and that-outside secondary lymphoid tissues-clonal evolution is retarded by diminished BCR-signaling. This transferrable, antigenic-specific murine B-cell clone (TCL1-192) provides a platform to study the types and sites of antigen-BCR interactions and genetic alterations that result and may have relevance to patients.
B lymphocytes | cell signaling | hematology | oncology | cancer M alignancies develop and progress to more virulent stages by accumulating genomic abnormalities that are often promoted by normal biologic functions, in a cell type-specific and stepwise manner. Several lines of evidence suggest antigen-binding site structural selection, mediated in part by B-cell antigen receptor (BCR)-(auto)antigen interaction, facilitates survival and expansion of precursor cells and leukemic cells in chronic lymphocytic leukemia (CLL) (1, 2) . CLL cells often use restricted IGHV genes that frequently associate with specific IGHD and IGHJ segments to code their BCRs (1-3), yielding Igs with characteristic HCDR3 regions (stereotyped BCRs). Such stereotyped BCRs often pair with discrete IGLV and IGLJ segments (4, 5) .
CLL clones can be subgrouped based on the presence (M-CLL) or absence (U-CLL) of IGHV mutations (6) , with more U-CLLs exhibiting stereotyped receptors than M-CLLs (4, 7). U-CLL BCRs are more often polyreactive, binding a diverse panel of antigens, than M-CLL BCRs, which are more restricted in antigen reactivity (8) . Clinically, U-CLL patients often have worse clinical outcomes than M-CLL patients (9, 10) , suggesting that degrees of BCR polyreactivity, and therefore (auto)antigen binding, affect CLL disease progression (1, 2) . Despite this evidence, it has been conjectured that rather than specific antigens or classes of antigens driving CLL, structural complementarities between framework regions and HCDR3s of CLL BCRs permit cell-autonomous interactions that lead to BCR signaling (11) .
Leukemic B cells of Eμ-TCL1 transgenic (TCL1) mice, a murine model of CLL, exhibit many features of CLL (12, 13) . TCL1 mice develop clonal CD5 + leukemias with stereotyped BCRs binding exo-and autoantigens such as DNA, cardiolipin, phospholipids, apoptotic cells, or microbes, which can be targets of human CLL Igs (14) (15) (16) . B-lymphocytes reactive with phosphatidylcholine (PtC), a phospholipid component of biological membranes in every cell of the body, use predominantly IGHV11 or IGHV12 genes, are abundant in the normal mouse B-1 subset, and are enriched in the peritoneal and pleural cavities (17) . In addition, anti-PtC IgMs are found in normal individuals (18) , CLL patients (19) , TCL1 mice (14) , and patients with systemic lupus erythematosus (20) .
Here, we endeavored to understand (auto)antigen-promoted leukemia progression by following the evolution of PtC-binding B cells from a single TCL1 transgenic mouse after serial transfers into SCID mice. We identified natural selection for a leukemic Bcell clone (TCL1-192) binding this specific autoantigen and exhibiting a more virulent behavior with faster growth kinetics than the standard TCL1 model. Notably, despite the clonal nature of the cell line, it displayed different efficiencies and outcomes to BCR signaling based on the site of cell residence in vivo.
Results
Surface Membrane IgM of Normal and TCL1 B-1 Cells Bind PtC. Using fluorescein-encapsulated liposomes made from distearoyl-phosphatidylcholine (21), we analyzed CD5 + B cells from WT and Eμ-TCL1 animals to compare PtC binding. Splenic B-2 cells in WT or preleukemic TCL1 mice did not bind PtC, but polyclonal peritoneal B-1 cells isolated from WT mice at various ages (3-10 mo)
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These studies indicate that autoantigen-reactivity plays a role in the progression of a murine leukemia that models human chronic lymphocytic leukemia. This indication is consistent with the notion that chronic lymphocytic leukemia evolves by selection of normal B cells that bind autoantigen via the B-cell antigen receptor.
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This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. 1073/pnas.1300616110/-/DCSupplemental. contained 19-22% PtC-binders and peritoneal B-1 cells from young and old TCL1 mice varied in PtC binding ability (15-36%) . Splenic CLL cells from moribund leukemic TCL1 mice (12-15 mo old) had even more diverse PtC-binding capacity, ranging from only 0.3-13% (SI Appendix, Fig. S1 A-C).
PtC binding by CLL cells in TCL1 mice (SI Appendix, Fig. S1D ) was blocked by preincubating cells with F(ab′) 2 (Fig. 1A) . By IGHV-D-J sequence analyses, this mouse contained two expanded B-cell clones; the major clone exhibited an IGHV11 rearrangement (58% of sequences) and the minor clone an IGHV12 rearrangement (25% of sequences); the remaining cells expressed a series of IGHV1 and IGHV2 genes (Fig. 1B and SI Appendix, Table S1 ).
TCL1 clones propagate CLL in recipient mice after adoptive cell transfer (12, 22 (Fig. 1, first transfer) .
Nonselected splenic lymphocytes isolated from the first moribund recipients (∼6 mo posttransfer) were then injected into other SCID mice; transfers were repeated for a total of four times. With each transfer, recipient mice had shortened survival. Recipients of the first and second transfer died in 6 and 2 mo, respectively. By the third and fourth transfers, survival diminished to ∼6 wk. Impor- tantly, as disease became more aggressive at each transfer, the PtC-binding population expanded and eventually became the major population in spleen and peritoneum (Fig. 1A) (P < 0.001), suggesting that BCR-autoantigen stimulation promoted CLL progression. Although PtC-binders were the major population after the second transfer, 43-53% TCL1-192 cells did not react with PtC; all PtC-binders (100%) and almost all nonbinders (98%) used identical IGHV11-IGHD1-IGHJ1/IGLVκ14-IGLJκ4 (Fig. 1B) . At the end of the third transfer and all subsequent transfers, only one IGHV-(D)-J sequence was found (IGHV11-IGHD1-IGHJ1/ IGLVκ14-IGLJκ4), even though some still failed to bind PtC to an appreciable degree after four transfers. Notably, replacement mutations in the IGV genes of these rearrangements were not found, consistent with their B-1 cell origin (23) . We named this clonal B-cell line with enhanced PtC binding and more rapid kinetics "TCL1-192."
To understand migratory and growth characteristics of TCL1-192, we analyzed seeding and expansion sites of retro-orbitally injected cells at weekly intervals. In fourth-transfer mice, B220 + CD5 + cells were detected in the spleen (SP) at week 1, and by week 3 in the blood and peritoneal cavity (PC). Lymphocyte infiltration in the liver was observed later (≥4 wk). By week 6, TCL1-192 cells were found in spleen, occasional inguinal lymph nodes (LNs), bone marrow (BM), and liver of all recipient mice (SI Appendix, Fig. S2 A and B).
TCL1-192 cell proliferation in different locales was measured by injecting BrdU intraperitoneally 24 h before killing at week 6. Divided cells were found mainly in secondary lymphoid tissues; cells from spleens and inguinal LNs contained ∼20% BrdUlabeled cells, whereas only 2-3% divided cells were found in the peritoneum, BM, or peripheral blood (PB) (SP: 16.5% ± 0.02 and LN: 21.3% ± 0.03 vs. PC: 2.7% ± 0.04, BM: 2.3% ± 0.06, and PB: 1.9% ± 0.02, P < 0.001) (SI Appendix, Fig. S2C ), suggesting secondary lymphoid tissues, not central or peripheral sites, are preferred areas for leukemic cell proliferation.
PtC-Reactive TCL1-192 Cells from Spleens Have a Cell Growth and
Disease Progression Advantage. TCL1-192 cells differing in PtCbinding capacity were studied using a gating strategy shown in Fig.  2A . Because PtC binding was smIg-dependent, we analyzed smIgM density on PtC + and PtC − binding cells. The PtC-binding fraction had higher mean smIgM density than the non/poor PtC-binding fraction (mean fluorescence intensity: 23,270 ± 3,377 vs. 13,760 ± 1,524, P = 0.016) (Fig. 2B) . Consistent with enhanced PtC binding with serial adoptive transfers, smIgM density increased on TCL1-192 cells most markedly for cells in the PC (Fig. 2C) .
Differences in BCR stimulation in the PtC + and PtC − fractions were studied by measuring Ca 2+ flux after stimulation with F(ab′) 2 fragments of anti-IgM pAbs. Splenic PtC binders responded better than nonbinders. However, only low percentages of PtC + and PtC − cells from the peritoneum responded to anti-IgM stimulation, despite increased smIgM density (Fig. 2D) .
Because BCR-signaling promotes B-1 proliferation and survival of PtC binders in vitro (24, 25) or spleen had enlarged spleens and more leukemic cells in PC and spleen ( Fig. 3 B and C) . Cell counts in blood were also elevated, although not significantly (Fig. 3C) (Figs. 2 and 3) , we checked if their BCRsignaling phenotypes were similar to normal murine peritoneal B-1 cells that are less responsive to smIgM stimulation than splenic B-1 cells (24, 26) . Interestingly, compared with splenic cells, TCL1-192 CLL cells from the PC had elevated surface IgM (Fig. 4A) , elevated basal levels of phosphorylated phospholipase Cγ2 (PLCγ2) and spleen tyrosine kinase (SYK) (Fig. 4B) , and diminished responsiveness to anti-IgM pAbs and PtC liposome stimulation in vitro, as measured by calcium flux (Fig. 4 C and D) . Similar to PC but different from splenic TCL1-192 cells, BM cells were also nonresponsive to anti-IgM stimulation (Fig. 4D, Upper) . These data correlate with cell proliferation results shown in SI Appendix, Fig. S2C , and suggest the BCR-stimulated CLL cell proliferation occurs mainly in secondary but not primary lymphoid tissues and extratissue compartments (PC and blood).
Importantly, the reduced Ca 2+ mobilization in TCL1-192 cells from the PC could be induced by preincubating TCL1-192 splenocytes for 24 h with PtC liposomes or peritoneal lavage collected from recipient mice (Fig. 4D, Lower) , suggesting hyporesponsiveness is a result of factors in the PC or because of different concentrations of antigen in distinct compartments, as for normal murine B-1 cells (24) .
Next, we compared the fate of TCL1-192 cells injected directly into the PC or into the venous circulation. TCL1-192 cells injected intraperitoneally or retro-orbitally into mice were killed 1 or 5 wk after transfer. At week 1, intraperitoneally injected TCL1-192 cells mainly resided in the PC, whereas retro-orbitally injected TCL1-192 cells infiltrated spleen, peritoneum, and blood. By week 5, numbers of leukemic cells in all three sites for both injection conditions were indistinguishable. Notably, TCL1-192 cells that homed to the spleen exhibited superior proliferation, regardless of route of administration (SI Appendix, Fig. S2 D and E) . Collectively, the data suggest the splenic microenvironment supports expansion of CLL cells, and the peritoneal milieu induces quiescence and hyporesponsiveness, in part because of soluble factors.
Genetic Signatures of PtC-Binding Cells Suggest Heightened BCR Signaling in Splenic but Diminished BCR and NFκB Signaling in Peritoneal TCL1-192 Cells. Gene expression differences between PtC + and PtC − populations in different locales were compared for WT, preleukemic TCL1, and TCL1-192 mice. When comparing differences in PtC + vs. PtC − populations from peritoneum and spleen, a 1.5-fold cutoff was applied to identify candidate genes for further study (27) . Fifty-three genes differed between PtC + and PtC − spleen cells; these included regulators of B-cell proliferation (TNFRSF13B, −1.7×; TSC22D3, −1.96×; TK1, 1.5×) and genes related to mitotic progression (CNOT3, 1.5×; ESPL1, 1.75×; KIFC1, 1.5×). Four hundred fifty-one genes differed in PtC + versus PtC − PC cells; those down-regulated were involved in BCR, PI3K, ERK/MAPK, and NFκB signaling pathways (e.g., NFATC1/ 2, −2×; PLCγ2, −1.9×; PRKCB, −1.8×; POU2F2, −1.7×; MAPK9, −1.6×; RelA −1.9×), and up-regulated were anti-apoptotic (APIP, 1.5×; SGK3, 1.6×; TRIAP1, 1.8×) (Fig. 5 , Left, and SI Appendix, Figs. S3, S4A, and Tables S2 and S3). These features are similar to anergic circulating CLL cells that are unresponsive to sIgM-crosslinking, constitutively expressing phosphorylated ERK, MEK, and transactivated NF-AT (28) .
Among the 53 and 451 genes identified in splenic and peritoneal PtC binders versus nonbinders, only TK1 (1.5×) and SPIB (−1.7×) were found in both compartments. Therefore, a less stringent cutoff (1.3-fold, P < 0.05) was applied, identifying 101 genes of which 33 and 68 genes changed concordantly and discordantly in spleen and peritoneum (SI Appendix, Table S4 and Fig. S4B) . The 68 discordant genes that were highly expressed in splenic PtC Results from the comparison of gene-expression differences between splenic and peritoneal PtC + cells support active BCR, NFκB, and PI3K signaling in splenic but not PC PtC + cells. In total, 272 genes were altered >twofold in splenic versus peritoneal PtC + but not PtC − cells (SI Appendix, Table S5 ); those up-regulated genes in splenic PtC + cells were involved in BCR and PI3K pathways: for example, POU2F2 (3.1×), PLCγ2 (2.9×), SHIP1/2 (2×), and PIK3CD(2×) (Fig. 5, Right) . To validate the microarray analyses, genes involved in these pathways were tested by realtime PCR and had the same pattern (SI Appendix, Fig. S3C ). Because analyses of expression profiles of patient CLL cells from LN, BM, and blood suggest that cells residing in LNs are more proliferative than those in the other sites and the level of proliferation correlates with clinical course (29), we compared the human CLL and murine TCL1-192 genetic profiles. Interestingly, of the 128 genes changed in human CLL LN versus periphery (PB or BM), a total of 24 and 4 were changed concordantly and discordantly in TCL1-192 SP versus PC genes, suggesting at least a 20% genetic signature overlap in lymphoid tissues versus periphery (SI Appendix, Table S6 ).
Taken together, the genetic signatures support that PtC + populations residing in spleen and peritoneum exhibit divergent phenotypic, functional, and signaling properties: the former representing cells with active BCR-, PI3K-, and NFκB-signaling pathways, and the latter cells hyporesponsive to BCR engagement, similar to normal B-1 lymphocytes (26, 30, 31) . These biologic and molecular observations may apply to CLL patients whose disease progression associates with unique BCR structures, antigen-reactivity, and signaling.
Discussion
Antigen binding and selection may be involved in the clonal evolution that leads to divergent clinical outcomes of patients with leukemic cells differing in BCR structure (32, 33) . Here, we used TCL1 mice to address this possibility in vivo, hoping to identify therapeutic targets to attenuate or cure the disease. By serially transferring into SCID mice splenocytes from a single TCL1 mouse that spontaneously developed oligoclonal B-cells expressing IGHV genes involved in PtC binding, we observed natural selection for PtC-binding leukemic cells (Fig. 1) . This process established an aggressive, transferrable, antigen-specific cell line (TCL1-192) that permitted comparisons of cells not binding PtC with those binding PtC and also cells residing in different anatomic sites (in or outside of primary and secondary lymphoid tissues). By comparing trafficking, triggering, and proliferation, we demonstrated a direct relationship between increased PtC binding and more robust BCR signaling, in part because of higher smIgM density, with disease virulence (Figs. 2 and 3 , and SI Appendix, Normal murine B-1 cells use germ-line versions of IGHV11 or IGHV12 to react with the autoantigen PtC (24) . We found that young, preleukemic TCL1 mice exhibited a polyclonal anti-PtC B-1 cell repertoire and that TCL1 mice with advanced disease had oligo-or monoclonal expansions of such B cells. PtC binding depended on smIgM (SI Appendix, Fig. S1D ), and cells with higher levels of smIgM bound PtC better (Fig. 2) . As with TCL1-192 (Figs.  3-5) , smIgM-antigen engagement leads to activation of signaling molecules affecting tumor cell behavior, and smIgM expression levels influence BCR signaling (34) . Of note, the smIgM of U-CLL patients, who generally have poor outcomes, is less down-modulated upon antigen binding and is more effective at signal transduction than for M-CLL patients (35, 36) .
Increased antigen binding can result from the development and selection of replacement mutations in IGVs, as can occur for M-CLL patients whose clones use a stereotyped BCR (37) . These cases can exhibit intraclonal diversification and selection of specific changes in IGLVκ (37), suggesting clonal evolution in human CLL may be partly driven by ongoing interactions with (auto)antigen (38) . However, we did not observe a change in BCR structure of TCL1-192 cells over time. This paradox may be because of their deriving from B-1 cells that rarely develop IGV mutations (23) . Moreover, TCL1 leukemias resemble U-CLL patient clones (14) that rarely accumulate IGHV mutations (6), which emerge as major components of the clone (39) . Thus, the observed increased reactivity with PtC over time suggests antigen selection and drive can lead to a more hostile leukemia by mechanisms other than IGV diversification and selection. In addition, it is important to highlight that not all tumor cells of the TCL1-192 clone bound PtC, even after several transfers (Fig. 1) . Although this finding could be because of differences in cell-cycle stage among clonal members, it could also reflect signaling mediated by other BCR-cross-reactive antigens or selection for an alternative type of BCR-signaling mediated by autoantigens in adjacent smIgs, as was recently identified in human CLL (11) .
TCL1-192 cells proliferated robustly in spleen and LNs but not in the PC, BM, and blood (SI Appendix, Fig. S2 ), consistent with normal splenic B-1 cells having a higher turnover rate (24, 26) . Furthermore, despite their increased smIgM density and PtC PtC + and PtC − populations sorted from fourth transferred mice were injected into six mice, and mice were killed 5 wk later. Cells from peritoneal washout, spleen and blood were harvested and analyzed for the total number of CLL cells (shown in C). Bar graphs indicate mean values and SD. Statistical analysis was performed with unpaired t test using GraphPad Prism software. **P < 0.01, ***P < 0.001.
binding, TCL1-192 cells residing in the peritoneum and BM, exhibited signaling properties similar to hyporesponsive B-1 cells that survive longer in vitro (31, 40) . These findings are reminiscent of human CL cells that proliferate more actively in LNs and less so in BM and blood, as demonstrated by K i -67 expression (29) , deuterium incorporation into newly synthesized DNA in vivo (41, 42) , and differential expression of activation-associated genes in LNs, BM, and blood (29) . Thus, both mouse and human CLL cells divide more actively in secondary lymphoid tissues [spleen and LNs for TCL1-192 (SI Appendix, Fig. S2 ), and LNs for human CLL (29, 42) ] and survive better in primary lymphoid areas (PC and BM for TCL1-192, and BM for human CLL), consistent with the idea that BCR signaling is more supportive of the proliferation of CLL cells located in secondary LNs than elsewhere (BM, blood). Our findings also suggest local influences controlling sitespecific functional differences are at least in part soluble (Fig. 4) , possibly antigen or cytokines differing in amount or type at the two locations. In this regard, it is noteworthy that human CLL cells may be tolerized by an apparently constant antigen receptor occupancy that is negated after incubation in vitro (43) . In mouse peritoneal B-1 cells (24, 31, 43) and some CLLs (28, 36) , continuous BCR occupancy may lead to impaired smIgM signaling, elevated intracellular Ca 2+ levels, sustained phosphorylation of PLCγ2, SYK, ERK1/2, MEK1/2, activated NFAT proteins, and weakened BCR and NFkB signaling. Here we found peritoneal and BM CLL cells, especially PtC-reactive ones, were hyporesponsive to smIg stimulation and PC cells expressed molecular signatures similar to hyporesponsive B-1 cells (Figs. 4 and 5 , and SI Appendix, Fig. S4B ).
The importance of local microenvironmental factors, either soluble or cellular, was highlighted by finding that unresponsive peritoneal TCL1-192 cells regained antigen responsiveness when transferred to new recipients, if they migrated to secondary lymphoid tissue (Fig. 3) . Conversely, active splenic TCL1-192 CLL cells were unable to respond to antigenic stimulation if precultured with peritoneal washout or after migration to the PC (Fig. 4) , consistent with gene-expression findings of suppressed BCRsignaling in peritoneal but not splenic PtC + vs. PtC − cells ( + T cells (44, 45) and the LN microenvironment appears to favor BCR and NFκB signaling in CLL (29) . It is noteworthy that the majority of genes differing between WT or young TCL1 B-1 PtC + and PtC + TCL1-192 cells suggest antigen-dependent BCR stimulation in CLL development (SI Appendix, Fig. S3 ). In addition, there is considerable similarity between human CLL and TCL1-192 genetic profiles in lymphoid tissue versus periphery (SI Appendix, Table S6 ).
Finally, because of its enhanced aggressiveness, this murine CLL-like cell line provides a shorter time-frame platform to study clonal evolution of genetic alterations in vivo. In addition, because of the defined BCR antigenic specificity, the influences of antigen binding and signaling on clonal progression are evaluable. Our findings that autoantigen-BCR interactions lead to clinical progression support the use of BCR-pathway inhibitors in human CLL (22, (46) (47) (48) .
Materials and Methods
Mice. (C57BL6×C3H)F1 WT mice, TCL1 transgenic mice (12) and CB17 SCID mice were housed under conventional barrier protection. Animal procedures were performed in accordance with The Feinstein Institute's Institutional Animal Care and Use Committee requirements. Mechanistic studies were carried out on cells frozen after the fourth transfer.
Flow Cytometric Analyses. Cellular PtC binding was determined by incubation with PE anti-CD45R/B220, APC anti-CD5 (BD Biosciences), and FITC-conjugated PtC liposomes, a kind gift from Stephen H. Clarke (Duke University, Durham, NC) (21) . For intracellular phospho-flow cytometry analysis, cells were exposed or not to 25 μM pervanadate, fixed with 16% (wt/vol) paraformaldehyde, permeabilized with ice-cold methanol, and exposed to Alexa647-conjugated p-SYK or pY-PLCγ2 antibodies (BD Biosciences). IGHV-D-J DNA Sequencing, Gene-Expression Profiling, and Data Analysis. cDNA sequencing was performed as described previously (6) . Sequences were compared with germ-line genes in the IMGT and GenBank databases. Nucleotide and amino acid sequences of V region segments from all major and minor clones were compared with each other and to those contained in the above databases using Ig-BLAST and IMGT/V-QUEST. For microarray analysis, combined spleen and PC B-1 cells from 15 3-mo-old WT mice, five 4-mo-old TCL1 mice, and CLL cells from two individual secondtransfer TCL1-192 mice were sorted into PtC + and PtC − populations. RNA extracted from these samples was hybridized to Sentrix Mouse WG-6 BeadChip (Illumina). Data were normalized using quantile normalization by BeadStudio software (Illumina). Ingenuity Pathway Analysis and GeneCards Batch Queries were applied to analyze the significant changed genes. Heatmaps of gene-expression values in each comparison were generated using heatmap.2 in the g-plots package of R (www.Rproject.org). analyze identified genes involved in the BCR signaling pathway that were differently expressed in peritoneal PtC + and PtC − cells (Left, n = 451, >1.5×), and PtC + cells isolated from spleen and peritoneum (Right, n = 272, >2×). Genes labeled in red and green were those identified as up-and down-regulated and other genes were those related to the regulated genes on the basis of the network analysis.
Real-time quantitative PCR assay using SYBR Green/ROX was performed in triplicates. Data were analyzed with the comparative CT (ΔΔCT, where CT is threshold cycle) method. Differences in CT were used to quantify the relative amount of PCR target contained within each well. Data were expressed as relative mRNA expression in reference to control, normalized to quantity of RNA input by performing measurements on an endogenous reference gene, GAPDH.
